PW Medtech Group (1358) H2 2025 earnings summary

Executive summary

• Revenue rose 7.1% year-over-year to RMB823.5 million, driven by Blood Purification and new Regenerative Medical Biomaterials sales.

• Gross profit fell 2.9% to RMB407.5 million, with margin declining to 49.5% due to pricing pressure from volume-based procurement.

• Net profit dropped 29.7% to RMB135.3 million; profit attributable to owners decreased 37.4% to RMB94.4 million.

• Adjusted net profit (non-HKFRS) declined 15.4% to RMB197.6 million, reflecting adjustments for share-based compensation, spin-off fees, and amortization.

• Final dividend of HK2.0 cents per share recommended, total annual dividend HK6.4 cents per share.

Financial highlights

• Blood Purification revenue surged 26.9% to RMB611.8 million, now 74.3% of total revenue.

• Infusion Set revenue fell 27.6% to RMB207.6 million due to expanded centralized procurement and price pressure.

• Regenerative Medical Biomaterials debuted with RMB4.1 million revenue.

• Gross margin dropped from 54.6% to 49.5% year-over-year.

• Operating profit decreased 31.9% to RMB122.3 million.

• Net finance income fell 15.1% to RMB42.7 million.

• Cash and cash equivalents at year-end: RMB1,802.8 million.

Outlook and guidance

• Focus remains on R&D, innovation, and expanding product portfolio in high-growth medical device segments.

• Continued cost control, efficiency enhancement, and market strategy optimization planned.

• Blood Purification expected to benefit from rising ESRD incidence and hemodialysis penetration.

• Regenerative Medical Biomaterials positioned for strong growth amid healthcare upgrades and aging population.